Experts at the FDA are set to review whether to approve ecstasy (MDMA) for PTSD treatment on June 4. This follows trials by Lykos Therapeutics. PTSD can stem from various traumatic events, including sustained abuse or trauma, and can disproportionately affect LGBTQ+ individuals.
Certain health conditions, like HIV, can also lead to PTSD. MDMA, commonly known as Ecstasy or Molly, was considered a therapeutic tool in the past. Despite its illicit status now, it once showed potential therapeutic use.
The FDA considers MDMA for PTSD as a new avenue after 25 years. It is a departure from typical treatments like anti-depressants. Street drugs like ecstasy are often laced with dangerous substances, highlighting risks in illicit drug use.
[
add
]
[
|
|
...
]